All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Venetoclax Plus Rituximab Continues to Demonstrate Survival and MRD Benefits in CLL

June 3rd 2022

Fixed-duration venetoclax plus rituximab has shown sustained progression-free survival, overall survival, and minimal residual disease benefits vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, regardless of high-risk biomarkers.

HITS Combo Meets Primary End Point for ORR in High-Risk Neuroblastoma

June 2nd 2022

The combination of the humanized anti-GD2 antibody naxitamab-gqgk, irinotecan, temozolomide, and sargramostim met its primary end point for objective response rate in patients with chemoresistant high-risk neuroblastoma.

Rolling Submission of BLA to FDA Completed for Omidubicel in Blood Cancers Requiring Transplant

June 2nd 2022

The rolling biologics license application submission to the FDA to support the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant has been completed.

Frontline BTK Inhibitors Improve OS in Real-World Patients with MCL

June 2nd 2022

The use of BTK inhibitors as a frontline treatment improved overall survival vs their deployment in subsequent lines of therapy in patients with mantle cell lymphoma, according to a real-world study (IRB-300004501) published in Blood Advances.

Fixed-Duration Ibrutinib/Venetoclax Significantly Prolongs PFS Over SOC in CLL and Comorbidities

June 2nd 2022

The fixed-duration combination of ibrutinib and venetoclax produced deep responses and improved progression-free survival vs chlorambucil plus obinutuzumab when used in previously untreated patients with chronic lymphocytic leukemia who were older and/or who had comorbidities, according to findings from the phase 3 GLOW trial.

OncLive Honors 13 Cancer Care Pioneers

June 2nd 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Montefiore Einstein Cancer Center Finds CAR T-Cell Therapy Effective in Black and Hispanic Patients

June 2nd 2022

Investigators at the Montefiore Einstein Cancer Center report that Black and Hispanic patients had outcomes and side effects following CAR-T treatment that were comparable to their white and Asian counterparts, according to findings from a study published in Bone Marrow Transplantation.

Second-Line Pemigatinib May Provide PFS Benefit in Cholangiocarcinoma With FGFR2 Fusions/Rearrangements

June 2nd 2022

Second-line treatment with pemigatinib may be linked with prolonged progression-free survival compared with other systemic therapies in patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

FDA Withdraws Approvals for Umbralisib in MZL, Follicular Lymphoma Due to Safety Concerns

June 1st 2022

The FDA announced that it has withdrawn approval for umbralisib, an oral inhibitor of PI3K-δ and CK1-ε manufactured by TG Therapeutics.

Heightened Histological Focus Fosters Treatment Advances in Non-clear Cell RCC

June 1st 2022

Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.

Antibody-Drug Conjugates May Represent the Future of HER2-Low Breast Cancer Treatment

June 1st 2022

Emerging data with novel antibody-drug conjugates such as trastuzumab deruxtecan-nxki, vic-trastuzumab duocarmazine, and disitamab vedotin are showing encouraging activity in HER2-low breast cancer.

NCCN Guidelines Affirm New Options for Resectable NSCLC

June 1st 2022

New systemic regimens are being integrated into the treatment paradigm for resectable non–small cell lung cancer in the neoadjuvant and adjuvant settings, expanding options for patients with earlier-stage disease who face a challenging prognosis.

Pathologic Complete Responses Can Help Inform Therapy De-escalation in Early-Stage, HER2+ Breast Cancer

June 1st 2022

Naomi Dempsey, MD, discusses the role of de-escalation therapy in early-stage, HER2-positive breast cancer and provides highlights from ongoing clinical trials in the space.

Oncology Nurses Recognized for Excellence in Patient Care, Advocacy and Leadership

June 1st 2022

Each May during Oncology Nursing Month, Florida Cancer Specialists & Research Institute, LLC recognizes two outstanding nurses within the practice.

Trastuzumab Deruxtecan Outperforms Standard of Care in Second-line HER2+ Breast Cancer

June 1st 2022

Heather McArthur, MD, MPH, described how the data from DESTINY-Breast03 reshapes the treatment landscape and offers added benefit to patients with brain metastases.

Novel Second-line Treatments Expand Therapeutic Options in Gastrointestinal Cancers

June 1st 2022

Kelsey Klute, MD, discusses the importance of frontline checkpoint inhibitors in advanced gastric cancer, the need for predictive biomarkers in hepatocellular carcinoma, and research investigating immunotherapy in HER2-negative gastric and esophagus cancer and esophagus and gastroesophageal junction cancer.

Investigators Explore Immunotherapy for NETs as Incidence Grows

May 31st 2022

To date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors.

Nurix Therapeutics Launches Expansion Cohort Evaluating NX-2127 in CLL

May 31st 2022

Nurix Therapeutics has initiated an ongoing phase 1 trial to examine NX-2127, an immunomodulatory oral BTK inhibitor, in patients with chronic lymphocytic leukemia.

Galinpepimut-S Plus Pembrolizumab Displays Early Efficacy in WT1+ Ovarian Cancer

May 31st 2022

Galinpepimut-S in combination with the PD-1 inhibitor pembrolizumab elicited a clinical benefit in patients with Wilms’ tumor-1-positive relapsed/refractory platinum-resistant advanced metastatic ovarian cancer, according to top line-line data from a phase 1/2 trial (NCT03761914).

Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care

May 31st 2022

The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.